Patient no. | Age/gender | EGFR mutataion | Treatment after acquired resistance | Grade 3–4 toxicities | Reduce dose |
---|---|---|---|---|---|
1 | 55/male | 21L858R | Icotinib 125 mg/tid + crizotinib 250 mg/bid | No | No |
2 | 65/female | 21L858R | Gefitinib 250 mg/qd + crizotinib 250 mg/bid | Aminotransferase rise | Gefitinib 250 mg/qd + crizotinib 200 mg/bid |
3 | 53/male | 21L858R | Icotinib 125 mg/tid + crizotinib 250 mg/bid | No | No |
4 | 49/male | 21L858R | Gefitinib 250 mg/qd + crizotinib 250 mg/bid | No | No |
5 | 62/female | 21L858R | Elotinib 150 mg/qd + crizotinib 250 mg/bid | Aminotransferase rise | Elotinib 150 mg/qd + crizotinib 200 mg/bid |
6 | 60/female | 19 exon deletion | Icotinib 125 mg/tid + crizotinib 250 mg/bid | No | No |
7 | 37/male | 19 exon deletion | Crizotinib 250Â mg/bid | No | No |
8 | 64/male | 21L858R | Crizotinib 250Â mg/bid | No | No |
9 | 71/female | 21L858R | Crizotinib 250Â mg/bid | Nausea | Crizotinib 200Â mg/bid |
10 | 64/female | 21L858R | Crizotinib 250Â mg/bid | No | No |
11 | 58/male | 21L858R | Crizotinib 250Â mg/bid | No | No |
12 | 41/female | 21L858R | Crizotinib 250Â mg/bid | No | No |
13 | 58/female | 21L858R | Crizotinib 250Â mg/bid | No | No |
14 | 53/female | 21L858R | Crizotinib 250Â mg/bid | No | No |